This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe
by Zacks Equity Research
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
Henry Schein Closes Merritt Buyout, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) is consistently trying to expand its Animal Health business.
Henry Schein to Offer CAS' Fully-Automated Cognivue Device
by Zacks Equity Research
Henry Schein (HSIC) is consistently working toward boosting its Medical segment.
Henry Schein MicroMD Software Gets ONC-Health IT Certificate
by Zacks Equity Research
Henry Schein's (HSIC) MicroMD receives ONC-Health IT Certificate from Drummond Group, boosting the company's technology and value-added service business.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact
by Zacks Equity Research
Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.
Henry Schein (HSIC) Tops Q2 Earnings and Revenues Estimate
by Zacks Equity Research
Henry Schein (HSIC) rides high on all four segments in Q2 delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions.
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
Here's Why Henry Schein is Worth Adding to Your Portfolio
by Zacks Equity Research
Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.
Henry Schein Grows on Strategic Buyouts, Competition Rife
by Zacks Equity Research
On Jun 15, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Henry Schein (HSIC) Up 5.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Rides on Global Growth, Strategic Deals
by Zacks Equity Research
On May 25 2017, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Pure Storage (PSTG) Posts Narrower-than-Expected Q1 Loss
by Zacks Equity Research
Pure Storage Inc. (PSTG) reported non-GAAP loss (including stock-based compensation) of 30 cents per share in the first-quarter of fiscal 2018, which was narrower than the Zacks Consensus Estimate by 8 cents.
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.
Henry Schein (HSIC) Tops Q1 Earnings and Revenues Estimate
by Zacks Equity Research
Headquartered in Melville, NY, Henry Schein Inc. (HSIC) is a global leading provider of healthcare products and services.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.
Henry Schein (HSIC) Poised on Solid Growth, Risks Remain
by Zacks Equity Research
On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Henry Schein Inks Agreement for Rijuven's CardioSleeve
by Zacks Equity Research
Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.
Henry Schein (HSIC) Tops Q4 Earnings and Revenues Estimates
by Zacks Equity Research
Henry Schein (HSIC) reported positive fourth quarter 2016 results with earnings and sales exceeding the Zacks Consensus Estimate.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
by Zacks Equity Research
Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).